Carcinoma, Non-Small-Cell Lung: all 6,645 studies

Page 44 of 67. Open to participants first (1,667), then studies with results posted, then the rest; newest registration first within each.

• Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT03909334Phase 2
• Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing CancerActive, not recruitingNCT03907852Phase 1/2
• A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLCStatus unknownNCT03904823Phase 2
• A Study of Anti-PD1 Antibody-activated TILs in Non-small Cell Lung CancerStatus unknownNCT03903887Phase 1/2
• Move for Surgery (MFS): Evaluating the Use of Wearable Technology for Preconditioning Before Thoracic SurgeryCompletedNCT03902834Not applicable
• Hypofractionated Radiotherapy Followed by Hypo-boost for Local Advanced NSCLCCompletedNCT03900117Phase 2
• A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid TumorsActive, not recruitingNCT03893955Phase 1
• Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic CancerCompletedNCT03892096
• Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.Active, not recruitingNCT03891953Phase 1
• Complication and Lung Function Impairment Prediction Using Perfusion and CT Air TrappingCompletedNCT03885765
• Consolidation Sintilimab After Concurrent Chemoradiation in Patients With Unresectable Stage III NSCLCStatus unknownNCT03884192Phase 3
• Analysis of Biopsy Specimens to Study Responses to PD-1 or PD-L1 TherapiesWithdrawnNCT03877250
• Sintilimab Combined With Metformin in First-Line Chemotherapy Refractory Advanced NSCLC PatientsStatus unknownNCT03874000Phase 2
• PDX Models From EGFR Mutant TumorsWithdrawnNCT03872440
• Radiomics Multifactorial Biomarker for Pulmonary NodulesCompletedNCT03872362
• Neoantigen-primed DC Vaccines Therapy for Refractory Lung CancerStatus unknownNCT03871205Phase 1
• LIFE - Lung Cancer, Immunotherapy, Frailty, EffectActive, not recruitingNCT03870464
• A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung CancerCompletedNCT03866993Phase 3
• A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung CancerTerminatedNCT03866980Phase 3
• A Study of Sintilimab or Placebo in Combination With Chemotherapy as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer With Wild-type EGFR After Failure With Platinum-Containing Chemotherapy.Status unknownNCT03863483Phase 2
• D-0316 in Patients With EGFR Positive Non Small Cell Lung CancerCompletedNCT03861156Phase 2
• Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced CancerActive, not recruitingNCT03860272Phase 1
• Pharmacokinetic Boosting of OsimertinibCompletedNCT03858491Early Phase 1
• Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR MutationStatus unknownNCT03856697Phase 3
• A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLCCompletedNCT03856411Phase 3
• Imaging Tumor-infiltrating T-cells in Non-small Cell Lung CancerCompletedNCT03853187Phase 2
• A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid TumorsCompletedNCT03849469Phase 1
• CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).Status unknownNCT03848611Phase 2
• A Study to Evaluate Immunotherapy Combinations in Participants With Lung CancerCompletedNCT03846310Phase 1
• Her2-positive Lung Cancer Treated With Dedicated DrugCompletedNCT03845270Phase 2
• Safety and Efficacy of LorbrenaCompletedNCT03844464
• Mitochondria-targeted System Therapy Combined With Radiofrequency Ablation for Early-stage Non-small Cell Lung CancerStatus unknownNCT03840408Not applicable
• KN046 in Patients With Advanced Non-small Cell Lung CancerTerminatedNCT03838848Phase 2
• The Tracking Molecular Evolution for NSCLC (T-MENC) StudyStatus unknownNCT03838588
• NADIM II: Neo-Adjuvant ImmunotherapyActive, not recruitingNCT03838159Phase 2
• Retrospective Epidemiological Study of Locally Advanced Non Small Cell Lung Cancer Patients in BrazilCompletedNCT03836469
• Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI ResistanceActive, not recruitingNCT03833440Phase 2
• Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR MutationActive, not recruitingNCT03833154Phase 3
• Dynamics of 18-FDG Uptake in Stage III/IV Non Small Cell Lung Cancer During First Line Pembrolizumab TreatmentCompletedNCT03832348Not applicable
• A Study of Sintilimab Compared With Docetaxel or Pemetrexed as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer After Failure With Platinum-Containing ChemotherapyStatus unknownNCT03830411Phase 2
• OMEGA, Local Ablative Therapy in Oligometastatic NSCLCStatus unknownNCT03827577Phase 3
• Dry Pleurodesis With Talcum and Afatinib is Used to Treat Patients With Non-Small Cell Lung CarcinomaStatus unknownNCT03827070Phase 1
• Immunotherapy SBRT Sensitization of the Programmed Death-1 (PD-1) EffectCompletedNCT03825510Phase 2
• Papaverine and Stereotactic Body Radiotherapy (SBRT) for Non Small Cell Lung Cancer (NSCLC) or Lung MetastasesActive, not recruitingNCT03824327Phase 1
• A Study to Evaluate the Safety and Efficacy of SH-1028 in Locally Advanced or Metastatic NSCLCStatus unknownNCT03823807Phase 2
• A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLCActive, not recruitingNCT03819465Phase 1
• A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal CancerCompletedNCT03819387Phase 1
• Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLCTerminatedNCT03818776Early Phase 1
• The Predictive Role of Programmed Death Ligand 1 (PD-L1) and Neutrophil to Lymphocyte Ratio (NLR) in Non-Small Cell Lung Cancer (NSCLC)Status unknownNCT03816657
• Avelumab Program Rollover StudyActive, not recruitingNCT03815643Phase 3
• A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation PositiveCompletedNCT03812809Phase 2
• A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid TumorsCompletedNCT03811652Phase 1
• The Efficacy and Drug Resistance Molecular Biology of Apatinib Combined With EGFR-TK1 Treated for Advanced Slow-progressed Non-Small Cell Lung Cancer (NSCLC)Status unknownNCT03811054Phase 2
• Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung CancerCompletedNCT03810807Phase 1
• Efficacy and Safety of SCT200 in Patients With Advanced Squamous Non-small Cell Lung CancerStatus unknownNCT03808701Phase 1
• Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and LungActive, not recruitingNCT03808662Phase 2
• Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10%Status unknownNCT03808480Phase 2
• A Study of Participants in Australia Who Have Non-small Cell Lung Cancer Being Treated With NivolumabCompletedNCT03804554
• Volatil Organic Compounds in Exhaled Air and Sweat After Thoracic Surgery for Carcinological ResectionStatus unknownNCT03803137Not applicable
• Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment FailureCompletedNCT03802240Phase 3
• Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung CancerTerminatedNCT03802058Phase 2
• Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung CancerCompletedNCT03801304Phase 2
• Apatinib Combined With Radiotherapy in Patient With BM From Drive Gene Negative NSCLCStatus unknownNCT03801200Phase 2
• A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung CancerActive, not recruitingNCT03800134Phase 3
• Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLCStatus unknownNCT03799601Phase 4
• Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor MutationsStatus unknownNCT03799094Phase 1/2
• Phase II Study on Sintilimab Combined With Docetaxel for Chemotherapy Failure Advanced NSCLC: the SUCCESS StudyCompletedNCT03798743Phase 2
• Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based RegimenWithdrawnNCT03792503Phase 4
• To Evaluate the Efficacy and Safety of SCT510 in the Treatment of Non-small Cell Lung CancerStatus unknownNCT03792074Phase 3
• Pharmacogenetics in Non Small Cell Lung CancerStatus unknownNCT03791151
• Osimertinib in Subjects With Advanced Non-Small Cell Lung Cancer EGFR-T790M Mutation-positiveCompletedNCT03790397
• Anlotinib Combined With Pemetrexed And Carboplatin as First-line Treatment in Advanced Nonsquamous NSCLCStatus unknownNCT03790228Phase 1
• A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung CancerCompletedNCT03789604Phase 3
• Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLCActive, not recruitingNCT03786692Phase 2
• T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLCTerminatedNCT03784599Phase 2
• Continued Access to RXDX-105CompletedNCT03784378Phase 1
• A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical PracticeCompletedNCT03782207
• Study of Anlotinib in Advanced Non-squamous NSCLC Patients in the Elderly Without Systemic Chemotherapy (ALTER-L006)Status unknownNCT03778853Phase 4
• Study of Anlotinib Combined With Pemetrexed in Patients With Advanced Nonsquamous NSCLCStatus unknownNCT03778138Phase 2
• Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung CancerTerminatedNCT03777124Phase 2
• PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung CancerActive, not recruitingNCT03774732Phase 3
• NSCLC Heterogeneity in Early Stage Patients and Prediction of Relapse Using a Personalized "Liquid Biopsy"Status unknownNCT03771404Not applicable
• An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual DiseaseWithdrawnNCT03770299Phase 2
• Clinical Study of Anlotinib in Maintenance Treatment of Advanced NSCLCStatus unknownNCT03769805Not applicable
• Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLCActive, not recruitingNCT03769103Phase 2
• Anlotinib Plus Pemetrexed or Pemetrexed for Previously Untreated Elderly (>=70) or PS=2 Non-squamous NSCLCStatus unknownNCT03768037Phase 4
• Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)Active, not recruitingNCT03767348Phase 2
• Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung CancerStatus unknownNCT03766490Not applicable
• Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M NegativeStatus unknownNCT03765775Phase 2
• NGS Combined With RNAseq on Tumor Immune Escape in NSCLCStatus unknownNCT03764917
• Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)TerminatedNCT03762122Phase 2
• Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in BelgiumCompletedNCT03761901
• Apatinib Combined With Chemotherapy for NSCLC Patients Without T790M MutationStatus unknownNCT03758677Phase 2
• Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M NegativeCompletedNCT03758287Phase 1/2
• Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line（ALTER-L020）Status unknownNCT03755869Phase 4
• A Phase I Study of TQ-B3456 on Tolerance and PharmacokineticsTerminatedNCT03754244Phase 1
• X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain MetastasesActive, not recruitingNCT03753685Phase 2
• A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)CompletedNCT03752398Phase 1
• Anlotinib Combined With Docetaxel for Advanced Non-squamous Non-Small Cell Lung CancerStatus unknownNCT03750916Phase 2
• Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung CancerStatus unknownNCT03749213Phase 2

← Carcinoma, Non-Small-Cell Lung overview